Welcome to our dedicated page for Agios Pharmaceuticals news (Ticker: AGIO), a resource for investors and traders seeking the latest updates and insights on Agios Pharmaceuticals stock.
Agios Pharmaceuticals Inc. (AGIO) is a leader in developing therapies for rare hematologic and genetic disorders through its groundbreaking work in cellular metabolism. This page provides investors and industry professionals with timely updates on AGIO’s clinical advancements, regulatory milestones, and strategic initiatives.
Discover official press releases covering AGIO’s progress in treating conditions like pyruvate kinase deficiency, thalassemia, and sickle cell disease. The curated news includes updates on clinical trials, FDA communications, research collaborations, and pipeline expansions. Each update is sourced to ensure accuracy and relevance for informed decision-making.
Key areas of coverage include novel therapeutic developments, regulatory submissions, and strategic partnerships that underscore AGIO’s role in advancing precision medicine. Bookmark this page to stay informed about the company’s contributions to transforming rare disease treatment through metabolic science.
Agios Pharmaceuticals (Nasdaq: AGIO) has announced its presentation schedule at the RBC Capital Markets Global Healthcare Conference on May 16, 2024, at 9 a.m. ET. This conference is a key opportunity for investors and analysts to engage with the company.
Participants can access a live webcast via the Investors section of the Agios website, with an archived replay available for two weeks post-presentation. Agios is recognized for its innovative work in cellular metabolism and offers therapies for rare diseases, including a first-in-class pyruvate kinase activator for PK deficiency.
The company’s pipeline includes investigational therapies for conditions such as sickle cell disease and thalassemia, reinforcing its commitment to developing solutions for serious health challenges.
Agios Pharmaceuticals (Nasdaq: AGIO) announced the appointment of Jeffrey Capello to its board of directors, effective immediately, following the upcoming departure of Paul Clancy at the end of his term on June 13, 2023. Capello brings over 30 years of experience in life sciences, including his role as CFO at Biogen, where he improved financial outcomes and R&D pipelines. Agios CEO Brian Goff expressed enthusiasm for Capello’s experience and international perspective, emphasizing the board's commitment to long-term value creation. Capello aims to support Agios’s mission of developing transformative medicines for rare diseases. The company is advancing its pipeline, including treatments for PK deficiency and other rare hematological conditions.
Agios Pharmaceuticals (Nasdaq: AGIO) will host a conference call and live webcast on May 4, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results and other business highlights. The event will be accessible via the company's website, with an archived replay available shortly after the event.
The company is recognized for its pioneering work in cellular metabolism and markets the first disease-modifying therapy for patients with PK deficiency. Agios is actively advancing a clinical pipeline focused on various rare diseases and has a potential therapeutic candidate in preclinical development for phenylketonuria.
On April 12, 2023, Totus Medicines announced the appointment of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero to its Scientific Advisory Board (SAB). The company, known for its innovative drug discovery platform, aims to revolutionize oncology treatment using its Totus Accel™ technology, which significantly speeds up drug discovery processes. Dr. Cantley is renowned for discovering the PI3K pathway, while Dr. Rugo has established critical clinical strategies for rapid drug approvals. Dr. Tabernero leads several oncology initiatives at Vall d'Hebron Institute. This diverse SAB aims to guide Totus as it progresses into clinical trials, enhancing its capabilities in addressing complex oncology challenges, especially targeting the mutated oncogene PI3Kα.
FAQ
What is the current stock price of Agios Pharmaceuticals (AGIO)?
What is the market cap of Agios Pharmaceuticals (AGIO)?
